Valemetostat Tosilate: First Approval

Valemetostat tosilate (valemetostat; EZHARMIA(®)), a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2 (EZH1/2), is being developed by Daiichi Sankyo Company, Ltd for the treatment of various haematological malignancies and solid tumours, including typ...

Descripción completa

Detalles Bibliográficos
Autor principal: Keam, Susan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705507/
https://www.ncbi.nlm.nih.gov/pubmed/36380144
http://dx.doi.org/10.1007/s40265-022-01800-5
_version_ 1784840298818437120
author Keam, Susan J.
author_facet Keam, Susan J.
author_sort Keam, Susan J.
collection PubMed
description Valemetostat tosilate (valemetostat; EZHARMIA(®)), a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2 (EZH1/2), is being developed by Daiichi Sankyo Company, Ltd for the treatment of various haematological malignancies and solid tumours, including types of non-Hodgkin lymphomas (NHL). Valemetostat was approved in Japan in September 2022 for the treatment of patients with relapsed or refractory adult T-cell leukaemia/lymphoma (R/R ATL), a subtype of NHL. This article summarizes the milestones in the development of valemetostat leading to this first approval for R/R ATL.
format Online
Article
Text
id pubmed-9705507
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-97055072022-11-30 Valemetostat Tosilate: First Approval Keam, Susan J. Drugs AdisInsight Report Valemetostat tosilate (valemetostat; EZHARMIA(®)), a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2 (EZH1/2), is being developed by Daiichi Sankyo Company, Ltd for the treatment of various haematological malignancies and solid tumours, including types of non-Hodgkin lymphomas (NHL). Valemetostat was approved in Japan in September 2022 for the treatment of patients with relapsed or refractory adult T-cell leukaemia/lymphoma (R/R ATL), a subtype of NHL. This article summarizes the milestones in the development of valemetostat leading to this first approval for R/R ATL. Springer International Publishing 2022-11-15 2022 /pmc/articles/PMC9705507/ /pubmed/36380144 http://dx.doi.org/10.1007/s40265-022-01800-5 Text en © Springer Nature 2022, corrected publication 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle AdisInsight Report
Keam, Susan J.
Valemetostat Tosilate: First Approval
title Valemetostat Tosilate: First Approval
title_full Valemetostat Tosilate: First Approval
title_fullStr Valemetostat Tosilate: First Approval
title_full_unstemmed Valemetostat Tosilate: First Approval
title_short Valemetostat Tosilate: First Approval
title_sort valemetostat tosilate: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705507/
https://www.ncbi.nlm.nih.gov/pubmed/36380144
http://dx.doi.org/10.1007/s40265-022-01800-5
work_keys_str_mv AT keamsusanj valemetostattosilatefirstapproval

Ejemplares similares